Peptidomimetic
A synthetic compound designed to mimic the biological activity of a natural peptide while having a modified chemical structure that may improve stability, bioavailability, or resistance to enzymatic degradation. Peptidomimetics bridge the gap between traditional peptide drugs and small molecule drugs.
Technical Context
Peptidomimetics retain key structural features (pharmacophores) enabling receptor binding but replace the peptide backbone with more stable chemical scaffolds. Strategies include: backbone modification (N-methylation, reduced amide bonds, peptoids with side chains on nitrogen), non-natural amino acid incorporation, beta-peptides (using beta-amino acids with an extra methylene group), and entirely non-peptide small molecules designed from peptide pharmacophore templates. Some approved drugs classified as peptides have peptidomimetic features. Relugolix and elagolix are orally bioavailable GnRH antagonists that represent the extreme end of peptidomimetic design — they are small molecules derived from peptide receptor pharmacology.